TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3588512
Drug: Disopyramide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide administered as a bolus injection of 150 mg over 5 min.
Study: 3588512
Drug: Disopyramide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide administered as a bolus injection of 150 mg over 20 min.
Study: 3588512
Drug: Disopyramide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide administered over 5 min.
Study: 3588512
Drug: Disopyramide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide administered over 20 min.
Study: 12660530
Drug: Indinavir/ritonavir (IDV/RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (IDV/RTV) 800 mg/100 mg q12h
Study: 12660530
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (IDV) 800 mg q8h
Study: 11908356
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation dentifrice containing 5.0% potassium nitrate and 0.454% stannous fluoride in a silica base
Study: 11908356
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available nondesensitizing control dentifrice (Colgate Winterfresh Gel)
Study: 7877829
Drug: Fat Mobilisation
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat Mobilisation System (FMS) - bandaging with elasticated bandages soaked in active solution able to lower body temperature by 2-3 degrees C
Study: 29655779
Drug: VERSAFIBE™ 2470
Approvals — FDA: no, EMA: no, PMDA: no
Description: VERSAFIBE™ 2470 resistant starch muffin top (11.6 g TDF)
Study: 29655779
Drug: Control muffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control muffin top (0.9 g TDF)
Study: 28932087
Drug: 13C‐urea breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13C‐urea breath test (UBT) with new test meal after 29 days of esomeprazole 40 mg
Study: 24576686
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (within normal physiologic range)
Study: 24576686
Drug: Gonadotropin releasing
Normalized name: Gonadotropin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin releasing hormone antagonist
Study: 17414590
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + low-dose glimepiride + ADA diet + physical activity
Study: 17414590
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + ADA diet + physical activity
Study: 17414590
Drug: ADA diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA diet + physical activity (no drugs)
Study: 11902986
Drug: terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine (250 mg/d for 12 or 16 weeks)
Study: 11902986
Drug: itraconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: itraconazole (400 mg/d for 1 week in every 4 for 12 or 16 weeks)
Study: 11902986
Drug: subsequent terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: subsequent terbinafine treatment
Study: 8291967
Drug: Functional Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional Electrical Stimulation (FES) therapy for shoulder muscles (supraspinatus and posterior deltoid), up to 6 hours a day for 6 weeks
Study: 29429459
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii powder combined with azithromycin sequential therapy
Study: 29429459
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment combined with azithromycin sequential therapy
Study: 26164587
Drug: 100% O(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% O(2) administration
Study: 26164587
Drug: Sham O(2)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham O(2) administration
Study: 22985547
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy guide
Study: 21575939
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg misoprostol inserted into the posterior vaginal fornix 3 hours before OH
Study: 21575939
Drug: Vaginal examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal examination without misoprostol administration (control)
Study: 17506119
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (600 microg Cr(+3)) with biotin (2 mg)
Study: 9186096
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.5 mg/ml for 3 1/2 minutes)
Study: 9186096
Drug: 5-fluorouracil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (50 mg/ml for 5 minutes)
Study: 1357551
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (500 micrograms)
Study: 1357551
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline (500 micrograms) after 7 days
Study: 17989308
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart CSII
Study: 17989308
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro CSII
Study: 15667599
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg) inhalation
Study: 15667599
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of caffeine
Study: 10613642
Drug: Natural streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural streptokinase (nSK) 1.5 million units, one-hour intravenous infusion
Study: 10613642
Drug: Recombinant streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant streptokinase (rSK) 1.5 million units, one-hour intravenous infusion
Study: 7844604
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion fluorouracil (5FU) 200 mg/m2/d via a Hick‐man line for 6 months with epirubicin 50 mg/m2 IV and cisplatin 60 mg/m2 IV every 3 weeks for eight courses
Study: 7844604
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (control group)
Study: 1742815
Drug: 0.25 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg.kg‐1 ketamine iv
Study: 1742815
Drug: 0.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg.kg‐1 ketamine iv
Study: 31353126
Drug: Vocal Facilitating
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocal Facilitating Techniques (VFTs); 10 individual sessions, twice a week
Study: 31353126
Drug: Manual Circumlaryngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Circumlaryngeal Therapy (MCT); 10 individual sessions, twice a week
Study: 28796913
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g foam
Study: 28796913
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 μg/g and betamethasone 0.5 mg/g gel
Study: 28796913
Drug: Cal/BD foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD foam and gel vs. latest topical treatment (LTT)
Study: 27531752
Drug: Cal/BD gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cal/BD gel
Study: 25731215
Drug: Insulin needle
Normalized name: BD Regular Insulin Needle 19gx1"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin needle
Study: 19028932
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid supplements
Study: 14759453
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (heparin plus nafamostat, 0.2 mg/kg bolus followed by 2.0 mg/kg/h during cardiopulmonary bypass)
Study: 14759453
Drug: Aprotinin (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (heparin plus aprotinin, 2.0 x 10(4) KIU/kg)
Study: 11060418
Drug: Nadroparin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (low molecular weight heparin)
Study: 3549083
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cyclophosphamide, dipyridamole, and warfarin)
Study: 3549083
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among patients with IgA nephritis (n = 27)
Study: 3549083
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) among patients with IgA nephritis (n = 21)
Study: 3549083
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cyclophosphamide, dipyridamole, and warfarin) among matched pairs (n = 23)
Study: 3549083
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) among matched pairs (n = 23)
Study: 30945105
Drug: Dexmedetomidine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (30 µg)
Study: 22699827
Drug: Overground therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overground therapy
Study: 17586139
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of mifepristone once every 14 days for six cycles
Study: 15680804
Drug: Early low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early low-dose steroid therapy (methylprednisolone, 2 mg/kg loading dose followed by 2 mg/kg per day)
Study: 10605950
Drug: Low-dose wine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose wine group
Study: 10605950
Drug: High-dose wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose wine group
Study: 2228846
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination (SDD) with initial systemic cefotaxime (500 mg tid for 5 days)
Study: 2228846
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A (antibiotics that disturb colonization resistance)
Study: 2228846
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group B (antibiotics not affecting colonization resistance)
Study: 356244
Drug: Voltaren (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren (diclofenac sodium) 50 mg
Study: 23644549
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg every 4 weeks
Study: 25387477
Drug: golimumab 100
Normalized name: golimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 100 mg after dose adjustment
Study: 12233104
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment in group A (sick sinus syndrome with pacemaker)
Study: 12233104
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment in group B (atrial fibrillation without pacemaker)
Study: 12233104
Drug: Warfarin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosage in group A
Study: 12233104
Drug: Warfarin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin dosage in group B
Study: 7590502
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fish oil
Study: 7590502
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g corn oil (placebo)
Study: 2138595
Drug: naloxone 0.4
Normalized name: NALOXONE 0.4MG/0.4ML AUTOINJECTOR,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 0.4 mg (i.m.)
Study: 2138595
Drug: naloxone 4
Normalized name: naloxone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone 4 mg (i.v.)
Study: 2138595
Drug: naloxone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (both doses)
Study: 6766833
Drug: Phenobarbital 60
Normalized name: phenobarbital 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital 60 mg orally
Study: 6766833
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid 250 mg orally twice daily for 14 days + Phenobarbital 60 mg orally on day 4
Study: 31332998
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy for 6 months
Study: 23306584
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (approximately 3 ml/kg) combined with extracorporeal CO2 elimination
Study: 23306584
Drug: ARDSNet strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARDSNet strategy (approximately 6 ml/kg) without the extracorporeal device
Study: 22009805
Drug: Atracourium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracourium (5 mg in 0.5 ml)
Study: 22009805
Drug: cis-Atracourium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-Atracourium (5 mg in 0.5 ml)
Study: 22009805
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 ml normal saline)
Study: 20467603
Drug: 5-mm-long Rescue
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mm-long Rescue implants (Megagen)
Study: 20467603
Drug: 10-mm-long implants
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mm-long implants placed in augmented bone
Study: 20467603
Drug: Augmented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented group (10-mm-long implants)
Study: 7709928
Drug: Osteoporosis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoporosis therapy (specific intervention details not provided)
Study: 2311147
Drug: Propofol (2.0‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0‐2.5 mg.kg‐1 followed by a continuous infusion 0.1‐0.2 mg.kg‐1.min‐1)
Study: 2311147
Drug: Thiopentone (4.0‐5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4.0‐5.0 mg.kg‐1, infusion rate 0.16‐0.32 mg.kg‐1.min‐1)
Study: 6107500
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus levamisole 2.5 mg/kg/day for two consecutive days each week for 48 weeks
Study: 22032120
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray (64 microg per, 256 microg once daily)
Study: 22032120
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray (twice daily)
Study: 20069203
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg per day)
Study: 20069203
Drug: Nortriptyline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (20 mg per day)
Study: 20069203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propranolol and Nortriptyline (40 mg and 20 mg per day respectively)
Study: 15139978
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg weekly)
Study: 11838927
Drug: Short duration
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short duration antibiotic prophylaxis (2 days)
Study: 11838927
Drug: Long duration
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long duration antibiotic prophylaxis (7 days)
Study: 3383994
Drug: l-carnitine 20
Normalized name: L-Carnitine 200mg/1mL Solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine 20 mg/kg
Study: 3383994
Drug: l-carnitine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine 40 mg/kg
Study: 3383994
Drug: l-carnitine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine 60 mg/kg
Study: 3383994
Drug: l-carnitine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine infusion
Study: 27654729
Drug: Topical finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical finasteride 0.5%
Study: 22904030
Drug: Extended-release memantine
Normalized name: memantine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release memantine
Study: 17355732
Drug: Cilastatin co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilastatin co-administered with cyclosporin A
Study: 11996956
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg initially, increased to 40 mg if necessary)
Study: 10434236
Drug: Lornoxicam (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (8 mg tid for 3 days)
Study: 10434236
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg tid for 3 days)
Study: 7776115
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam and acetaminophen
Study: 1972011
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no beta-adrenergic agonist)
Study: 112656
Drug: ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketotifen (1 mg twice daily)
Study: 112656
Drug: disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: disodium cromoglycate (20 mg four times daily)
Study: 29499082
Drug: Traditional herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional herbal medicine (THM)
Study: 23810626
Drug: Go4it group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Go4it group treatment
Study: 22842422
Drug: One-stage reconstruction
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage reconstruction with a round permanent expander implant (Becker 25)
Study: 20085534
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (OM) 20 mg/day for 3 weeks, then up-titrated to OM 40 mg/day for 3 weeks, and subsequently to OM/HCTZ 40/12.5 mg/day or OM/HCTZ 40/25 mg/day as necessary
Study: 17073853
Drug: Dexpanthenol pastille
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexpanthenol pastille (200 mg, two pastilles sucked 30 min before operation)
Study: 17073853
Drug: Benzydamine hydrochloride
Normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine hydrochloride spray (four puffs, sprayed 30 min before operation and 5 min before anaesthesia induction)
Study: 15764945
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of two single‐standing titanium screw implants with cortical satellite implants and overdentures
Study: 8997168
Drug: IVIG-and-aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IVIG-and-aspirin
Study: 8997168
Drug: Aspirin-alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-alone
Study: 30824398
Drug: Resistance exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercises 2 days/week and aerobic exercises 1 day/week for 9 months with isoenergetic supplements containing 0, 10, 20, or 30 g whey protein twice daily
Study: 29399800
Drug: Alginos Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginos Oral Suspension (sodium alginate 1,000 mg three times daily)
Study: 29399800
Drug: Alginos Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginos Oral Suspension
Study: 27090863
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH (300 IU daily for 7 days)
Study: 23036134
Drug: Anticholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic therapy (solifenacin 5 mg initially, possible escalation to 10 mg, switch to trospium XR 60 mg)
Study: 23036134
Drug: OnabotulinumtoxinA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (100 U injection)
Study: 18294115
Drug: Anticholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic therapy
Study: 14616431
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of dexmedetomidine (2 microg x kg-1)
Study: 14616431
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of dexmedetomidine (2 microg x kg-1)
Study: 14616431
Drug: Peroral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral administration of dexmedetomidine (2 microg x kg-1)
Study: 10842420
Drug: 1.47 g
Normalized name: FERRIC OXIDE RED 2.3 g in 1 g / ZINC OXIDE 21.47 g in 1 g TOPICAL OINTMENT [DERMASEPTIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.47 g protein/kg body cell mass/d (marginal diet)
Study: 10842420
Drug: 2.94 g
Normalized name: ZINC OXIDE 2.94 g in 28 g TOPICAL CREAM [SPF 16 BRIGHTENING]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.94 g protein/kg body cell mass/d (adequate diet)